• A
  • A
  • A
日本語 Help
Science and technology information site for articles, patents, researchers information, etc.
Rchr
J-GLOBAL ID:201901020005834933   Update date: Mar. 22, 2025

Kagabu Masahiro

カガブ マサヒロ | Kagabu Masahiro
Affiliation and department:
Research field  (1): Obstetrics and gynecology
Research keywords  (2): Cancer Immunology ,  Gynecologic oncology
Research theme for competitive and other funds  (5):
  • 2022 - 2025 子宮癌肉腫に対する免疫逃避改善を誘導するウイルス療法の開発
  • 2021 - 2024 Development of tumor-host integrative therapies to overcome the refractory nature of uterine serous carcinoma
  • 2019 - 2022 卵巣明細胞癌に対するNEFHを標的とした新規治療法の開発
  • 2016 - 2019 The KANK1 pathway may be a novel therapeutic target for ovarian clear cell carcinoma
  • 2016 - 2019 Development of new viral therapy for improvement of immune escape mechanism in ovarian cancer
Papers (67):
  • tadahiro shoji, Eriko Takatori, Takayuki Nagasawa, Masahiro Kagabu, Tsukasa BABA, Tatsuhiko Shigeto, Yukiko Matsumura, Dai Shimizu, Yukihiro Terada, Manabu Seino, et al. Comparison of Treatment Outcomes Between First-Line Chemotherapy With or Without Bevacizumab for Advanced Ovarian Clear Cell Carcinoma (Tohoku Gynecologic Cancer Unit: TGCU-RS001A Study). Cancers. 2024. 16. 3801
  • SHO SATO, tadahiro shoji, Ami Jo, Haruka Otsuka, Marina Abe, Shunsuke Tatsuki, Yohei Chiba, Eriko Takatori, Yoshitaka Kaido, Takayuki Nagasawa, et al. Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer. Cancers. 2024
  • Shigekatsu Maekawa, Ryo Takata, Kie Sekiguchi, Masahiro Kagabu, Moe Toyoshima, Shinji Tamada, Kenta Takahashi, Daiki Ikarashi, Tomohiko Matsuura, Renpei Kato, et al. Prevalence of germline BRCA1/2 pathogenic variants in Japanese patients treated with castration-resistant prostate cancer and efficacy of CRPC treatment in real-world clinical practice. Japanese journal of clinical oncology. 2024. 54. 4. 489-497
  • Yohei Chiba, Masahiro Kagabu, Mitsumasa Osakabe, Rikako Ito, Sho Sato, Eriko Takatori, Yoshitaka Kaido, Takayuki Nagasawa, Tadahiro Shoji, Naoki Yanagawa, et al. A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system. Japanese journal of clinical oncology. 2024. 54. 4. 424-433
  • Yohei Chiba, Masahiro Kagabu, Mitsumasa Osakabe, Satoru Nihei, Sho Sato, Eriko Takatori, Yoshitaka Kaido, Takayuki Nagasawa, Tadahiro Shoji, Naoki Yanagawa, et al. Relative dose intensity of lenvatinib for uterine cancer does not affect the efficacy of combination therapy. Proceedings of the Biennial Meeting of Asian Society of Gynecologic Oncology. 2024. 0261-0261
more...
MISC (67):
more...
Books (6):
  • 婦人科がん薬物療法パーフェクトガイド
    診断と治療社 2021 ISBN:9784787824806
  • 産婦人科専門医のための必修知識
    日本産科婦人科学会事務局 2020 ISBN:9784907890223
  • エビデンスに基づいた癌化学療法ハンドブック
    メディカルレビュー社 2018 ISBN:4896007344
  • 産婦人科手術スタンダード
    メジカルビュー社 2017 ISBN:9784758317436
  • EBMがん化学療法・分子標的治療法
    中外医学社 2015 ISBN:9784498022461
more...
Education (2):
  • 1996 - 2000 Iwate Medical University Graduate School of Medical Science
  • 1990 - 1996 Iwate Medical University School of Medicine
Professional career (1):
  • 医学博士 (岩手医科大学)
Work history (9):
  • 2023/04 - 現在 Iwate Medical University
  • 2020/07 - 2023/03 Iwate Medical University School of Medicine
  • 2017/01 - 2020/06 Iwate Medical University
  • 2009/09 - 2016/12 Iwate Medical University
  • 2007/09 - 2009/08 University of Pennsylvania Ovarian Cancer Research Center visiting assistant professor
Show all
Committee career (3):
  • 2022/01 - 現在 日本婦人科ロボット手術学会 幹事
  • 2020/09 - 現在 日本婦人科腫瘍学会 子宮頸がん治療ガイドライン2022年版改訂委員会作成幹事
  • 2019/06 - 現在 日本臨床細胞学会 利益相反員会
Association Membership(s) (7):
日本がん免疫学会 ,  日本臨床細胞学会 ,  日本癌治療学会 ,  日本癌学会 ,  日本婦人科腫瘍学会 ,  日本産婦人科医会 ,  日本産科婦人科学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page